The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.
 
Eugene Shenderov
Stock and Other Ownership Interests - LifeImmune
Consulting or Advisory Role - GT Biopharma
Research Funding - Macrogenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending in field of allergy immunology and blood diagnostics
 
Angelo M De Marzo
No Relationships to Disclose
 
Tamara L. Lotan
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Su Jin Lim
No Relationships to Disclose
 
Mohamad E. Allaf
No Relationships to Disclose
 
Paul A. Moore
Employment - MacroGenics
Stock and Other Ownership Interests - GlaxoSmithKline; MacroGenics; Medtronic
Patents, Royalties, Other Intellectual Property - Have patents based on work at MacroGenics, Human Genome Sciences and Celera
 
Francine Chen
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Patents, Royalties, Other Intellectual Property - Patent Award/Application: 1. Antibodies Reactive with B7H3 immunological activity fragments thereof and Uses Thereof 2. Bi-Specific Monovalent Diabodies That Are Capable Of Binding to GPA33 And CD3, And Uses Thereof (Inst)
 
Kristina Sorg
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
Patents, Royalties, Other Intellectual Property - Patent No.: US 10,640,816 B2 (SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER -DEFINED REGION OF A CROSS -SECTIONED TISSUE)
 
Andrew M White
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
 
Briana Hudson
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
 
Paul A. Fields
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
 
Shaohui Hu
Other Relationship - CDI Laboratories
 
Samuel R. Denmeade
Research Funding - Astellas Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed to Pfizer receive patent maintenance fees
 
Kenneth J. Pienta
Leadership - CUE Biopharma; Keystone Biopharma
Stock and Other Ownership Interests - CUE Biopharma; Keystone Biopharma; Medsyn Biopharma; Oncopia Therapeutics
Consulting or Advisory Role - Akrevia Therapeutics; CUE Biopharma; GloriousMed Technology
Research Funding - Progenics
Travel, Accommodations, Expenses - CUE Biopharma
 
Christian P. Pavlovich
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Intuitive Surgical
Consulting or Advisory Role - Dendreon
Research Funding - Dendreon; Exact Imaging
 
Charles G. Drake
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Oncology; Werewolf Therapeutics
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Drew M. Pardoll
Stock and Other Ownership Interests - Aduro Biotech; Compugen; NexImmune
Consulting or Advisory Role - Amgen; MedImmune; Merck; Pfizer; Sanofi
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Compugen; Potenza Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties on patents licensed to Aduro, BMS, Potenza
 
Emmanuel S. Antonarakis
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi